AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global demand and ongoing market traction. Excluding the Humira platform, AbbVie sales ...

Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

In February 2025, stock markets fell on average. The S&P 500 (SPY) fell by 1.27%, due mostly to a decline in technology stocks. Investors reallocated their holdings into the drug sector. AbbVie (ABBV) ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

While sales of Skyrizi rose 57.9% on an operational basis, Rinvoq sales were up 47.1%. AbbVie’s other key drugs, Venclexta and Vraylar, coupled with significant contributions from newer drugs ...